SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123331
Filing Date
2024-11-07
Accepted
2024-11-07 16:10:48
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q pstx-20240930.htm   iXBRL 10-Q 2399801
2 EX-10.1 pstx-ex10_1.htm EX-10.1 48964
3 EX-31.1 pstx-ex31_1.htm EX-31.1 13080
4 EX-31.2 pstx-ex31_2.htm EX-31.2 13062
5 EX-32.1 pstx-ex32_1.htm EX-32.1 8429
6 EX-32.2 pstx-ex32_2.htm EX-32.2 8452
  Complete submission text file 0000950170-24-123331.txt   8709070

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240930.xsd EX-101.SCH 1212558
73 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240930_htm.xml XML 1287172
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39376 | Film No.: 241435750
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)